3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Head & Neck
26
Sarcoma
7
Gynecologic
6
Genitourinary
6
Gastrointestinal
6
Breast
6
Thoracic
5
Dermatologic
4
Endocrine
3
CNS
3
NET
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Brain Neoplasms
290
Glioblastoma
260
Glioma
202
Neuroblastoma
88
Neoplasms
62
Astrocytoma
56
Central Nervous System Neoplasms
54
Medulloblastoma
48
Breast Neoplasms
44
Melanoma
40
Sarcoma
39
Meningioma
39
Neurofibromatosis 1
38
Carcinoma, Non-Small-Cell Lung
38
Lung Neoplasms
37
Ependymoma
36
Osteosarcoma
31
Rhabdomyosarcoma
30
Neoplasm Metastasis
28
Sarcoma, Ewing
27
Rhabdoid Tumor
27
Diffuse Intrinsic Pontine Glioma
27
Recurrence
26
Oligodendroglioma
23
Gliosarcoma
22
Wilms Tumor
21
Pancreatic Neoplasms
21
Pheochromocytoma
20
Hepatoblastoma
20
Neurofibroma, Plexiform
19
Interventions
entrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
CNS
×
90 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02012699
2026-05-05
iCaRe2
University of Nebraska
Recruiting
999,999 enrolled
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA